AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00507975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine versus placebo
Description: The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
Study NCT00507975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine versus placebo
Description: The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
Study NCT04509414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
Study NCT04509414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
Study NCT02538718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Study NCT02538718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YTP(Ritodrine)
Study NCT04575259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Oral capsules
Study NCT02601105 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle Cream
Description: Lipoderm Cream alone
Study NCT02601105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centella Asiatica Cream
Description: 1% Centella Asiatica in lipoderm
Study NCT01107106 — intervention group
Intervention type: DRUG
Intervention: ellaOne® (ulipristal acetate)
Description: one single oral dose (30 mg tablet)
Study NCT00742898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-targeted opt-out rapid HIV screening
Description: Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
Study NCT00742898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-targeted opt-out rapid HIV screening
Description: Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
Study NCT02676440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment
Description: F13/T38
Study NCT02676440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: M26
Study NCT01750177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Television Viewing before mealtime
Study NCT01750177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Game Playing
Study NCT01750177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Use
Study NCT01750177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting quietly
Study NCT00978497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral BID
Study NCT00978497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598
Description: oral 200mg BID
Study NCT00978497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598
Description: oral 400mg BID
Study NCT00978497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon
Description: 180 μg dose via subcutaneous injection weekly
Study NCT00978497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon
Description: 180 μg dose via subcutaneous injection weekly
Study NCT00978497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
Study NCT00978497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
Study NCT01457833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBV implantation
Description: In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
Study NCT01457833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBV implantation
Description: In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
Study NCT01259440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Teleconferencing Care
Description: The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
Study NCT01259440 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Consists of one week telephone call and one month clinic visit
Study NCT04574661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
Study NCT04574661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Occlusion
Description: Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
Study NCT02639078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-0714
Description: One time dosing in capsule formulation
Study NCT02639078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: One time dosing in capsule formulation
Study NCT02913170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nattokinase
Study NCT02913170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03128788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
Study NCT04106713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Psychotherapy
Description: The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
Study NCT04106713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy (iCBT)
Description: The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues.
Study NCT04106713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (group CBT)
Description: The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
Study NCT01887990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: single dose IV 0.2 mg/kg ketamine
Study NCT01887990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline infusion
Study NCT00997932 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration
Description: Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
Study NCT05255198 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior versus lateral approach to hip joint
Study NCT03333083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (1200 mg once a day)
Study NCT03333083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine (300 mg once a day)
Study NCT02966600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise
Description: The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
Study NCT02966600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The control group followed its usual weekly physical activity routine
Study NCT04228900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized plan for improvement of nutrition
Description: For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
Study NCT04228900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systematic drug review
Description: Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
Study NCT03667599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home care
Description: This is the interventional arm where patients receive the transplant care in their homes.
Study NCT02179710 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adherence dashboard motivational interviewing
Description: These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
Study NCT00932555 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients under daily life treatment receiving Kogenate according to local drug information.
Study NCT03214250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Administer intravenously once every 28-day Cycle
Study NCT03214250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administer intravenously twice every 28-day cycle
Study NCT03214250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administer intravenously on 3 times every 28-day cycle
Study NCT03214250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administer intravenously 3 times every 28-day cycle
Study NCT01347177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconia-based adhesive bridge
Description: Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
Study NCT01347177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metal-based adhesive bridge
Description: The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
Study NCT02554552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY1201 2ml
Description: YY1201 2ml
Study NCT02554552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2ml
Description: phosphate buffered saline 2ml
Study NCT01192035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz or Nevirapine
Description: 2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz.
Study NCT01192035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted lopinavir
Description: 2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
Study NCT04936659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromodulation
Description: Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
Study NCT02554552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY1201 3ml
Description: YY1201 2ml
Study NCT00162149 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Nevirapine
Description: Tablets, Oral, 200 mg, Twice daily, 3 days.
Study NCT00162149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine + Atazanavir/Ritonavir
Description: Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
Study NCT00162149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine + Atazanavir/Ritonavir
Description: Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
Study NCT00162149 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atazanavir + Ritonavir
Description: Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
Study NCT02772276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
Study NCT02772276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 130 mg
Description: 130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
Study NCT02772276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
Description: 130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
Study NCT02772276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- two doses of 130 mg 24 hours apart
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
Study NCT02772276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
Study NCT02772276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuantumLeap
Description: Optical Renal Function Monitor (ORFM)
Study NCT02772276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiance
Description: Optical Renal Function Monitor (ORFM)
Study NCT02772276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)
Study NCT02772276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (2-part sensor)
Description: Optical Renal Function Monitor (ORFM)
Study NCT04550351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT04550351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group
Description: Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT04550351 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group
Description: Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
Study NCT03211429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
Study NCT03211429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai chi
Description: Tai Chi training in the Yang style of 24 movement
Study NCT03211429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postural control exercise
Description: Individually adjusted progressive and specific postural control training,
Study NCT02262156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention
Study NCT02262156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Description: Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned.
Study NCT02311556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging
Study NCT02921633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention letter